AMENDMENT AGREEMENTAmendment Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
AMENDMENT AGREEMENT (this “Agreement”), by and between Immunomedics, Inc. (the “Company”), a Delaware corporation and John Stubenrauch (the “Executive”), dated as of the 12th day of September, 2020.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “ Agreement”) is entered into as of March 30, 2020 and between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the “Company”) and John Stubenrauch (the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is entered into as of the February 25 (the "Effective Date") by and between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the "Company") and Bryan Ball, 7 Sugar Maple Row, Chester, NJ 07930 (the "Executive").
PRIVATE AND CONFIDENTIAL September 10, 2020 Gilead Sciences, Inc.Confidentiality Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances
GILEAD SCIENCES, INC. AMENDMENT NO. 1 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This Amendment No. 1 (this “Amendment”) to the Mutual Confidential Disclosure Agreement effective as of January 1, 2019 (the “Original Agreement”) is made effective as of June 30, 2019 (“Amendment Effective Date”) by and between lmmunomedics, Inc. (“Company”) and Gilead Sciences, Inc. (“Gilead”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Original Agreement to the extent defined therein.
MAKE WHOLE AGREEMENTMake Whole Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
MAKE WHOLE AGREEMENT (this “Agreement”), by and between Immunomedics, Inc. (the “Company”), a Delaware corporation and Dr. Behzad Aghazadeh (the “Executive”), dated as of the 12th day of September, 2020.
GILEAD SCIENCES, INC. MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • September 24th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
This Mutual Confidential Disclosure Agreement (“Agreement”), effective as of January 1, 2019 (the “Effective Date”), is by and between Immunomedics, Inc., a Delaware corporation with offices at 300 The American Road, Morris Plains, New Jersey 07950, USA (“Company”), and Gilead Sciences, Inc., a Delaware corporation with offices at 333 Lakeside Drive, Foster City, California 94404, USA (“Gilead”), and shall govern the disclosure by a party (“Discloser”) to the other party (“Recipient”).
